BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has received a consensus rating of “Moderate Buy” from the nineteen research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $127.8125.

BNTX has been the topic of several recent analyst reports. Berenberg Bank decreased their target price on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. HC Wainwright restated a “buy” rating and issued a $130.00 price target on shares of BioNTech in a research note on Monday, April 27th. UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $117.00 to $135.00 in a report on Wednesday, May 27th. Canaccord Genuity Group set a $142.00 price objective on shares of BioNTech in a research report on Wednesday, August 5th. Finally, Morgan Stanley reduced their price objective on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 8th.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $92.75 on Friday. The company has a market capitalization of $23.45 billion, a P/E ratio of -11.85 and a beta of 1.27. BioNTech has a 1-year low of $79.52 and a 1-year high of $124.00. The firm’s 50 day simple moving average is $91.94 and its two-hundred day simple moving average is $95.69. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $166.40 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.60) EPS. Research analysts expect that BioNTech will post -6.33 EPS for the current fiscal year.

BioNTech declared that its board has authorized a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to purchase up to 4.2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. Flossbach Von Storch SE bought a new stake in BioNTech in the 2nd quarter worth approximately $207,142,000. GSK plc purchased a new stake in shares of BioNTech during the 4th quarter worth approximately $84,711,000. BNP Paribas Financial Markets grew its holdings in shares of BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after purchasing an additional 451,124 shares in the last quarter. Finally, Bank of America Corp DE increased its position in BioNTech by 344.4% in the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after purchasing an additional 444,332 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.